Cleerly LABS vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cleerly LABS

by Cleerly

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Cleerly LABS provides comprehensive analysis of coronary CT angiography to detect and characterize atherosclerosis and stenosis for personalized heart disease management. In contrast, Tempus ECG-AF analyzes 12-lead ECGs to identify older patients at risk of developing atrial fibrillation. While both are FDA-cleared AI tools in cardiology, they address distinct cardiac conditions and utilize different diagnostic modalities, making them complementary rather than directly competitive.

Choose Cleerly LABS if…

Choose Cleerly LABS if your patient has undergone a CCTA scan and you require a comprehensive, AI-powered analysis of coronary atherosclerosis, including plaque volume, type, and and stenosis quantification. This tool is ideal for detailed cardiovascular risk stratification, visualizing coronary arteries in 3D, and tracking disease progression over time to personalize heart disease management.

View Cleerly LABS →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you are looking to identify patients aged 65 or older, without pre-existing AF, who are at an increased risk of developing new-onset atrial fibrillation/flutter within the next 12 months, using a standard 12-lead ECG. This tool supports earlier identification and follow-up for proactive management of AF risk in an eligible patient population.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cleerly LABS	Tempus ECG-AF
Pricing	Varies	Contact vendor
Deployment	Cloud, On-premise	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cleerly LABS	Tempus ECG-AF
Tool Name	Cleerly LABS	Tempus ECG-AF
Company	Cleerly	Tempus AI, Inc.
Description	AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management.	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
Primary Modality Analyzed	Coronary CT Angiography (CCTA)	12-lead ECG recordings
Key Feature 1	AI-powered CCTA image analysis	AI-based algorithm for 12-lead ECG analysis
Key Feature 2	Comprehensive coronary plaque assessment (volume, type)	Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months

Videos

Demos, reviews, and walkthroughs featuring Cleerly LABS and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of cardiac imaging or data does each tool analyze?

Cleerly LABS is designed for comprehensive analysis of coronary CT angiography (CCTA) images. Tempus ECG-AF, in contrast, analyzes 12-lead ECG recordings.

What specific cardiac conditions or risks do these tools help identify?

Cleerly LABS detects, quantifies, and characterizes atherosclerosis and stenosis, and can also detect ischemia with its ISCHEMIA module. Tempus ECG-AF identifies patients aged 65 or older at an increased risk of developing atrial fibrillation/flutter within the next 12 months.

Are there specific patient populations or criteria for using each tool?

Cleerly LABS is used for comprehensive CCTA analysis in personalized heart disease management. Tempus ECG-AF is specifically intended for patients 65 years or older who do not have pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

What kind of output or insights do these tools provide to aid clinical decision-making?

Cleerly LABS offers comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, 3D visualization, personalized heart disease risk assessment, and tracking of disease progression. Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation within 12 months, with results interpreted in conjunction with other diagnostic information and clinical history.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Cleerly LABS or Tempus ECG-AF

Backers

Who funded each tool's parent company.